These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28038383)

  • 1. Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients.
    Zhang Y; Cai P; Li L; Shi L; Chang P; Liang T; Yang Q; Liu Y; Wang L; Hu L
    Int Immunopharmacol; 2017 Feb; 43():210-218. PubMed ID: 28038383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
    Huang YH; Zhu C; Kondo Y; Anderson AC; Gandhi A; Russell A; Dougan SK; Petersen BS; Melum E; Pertel T; Clayton KL; Raab M; Chen Q; Beauchemin N; Yazaki PJ; Pyzik M; Ostrowski MA; Glickman JN; Rudd CE; Ploegh HL; Franke A; Petsko GA; Kuchroo VK; Blumberg RS
    Nature; 2015 Jan; 517(7534):386-90. PubMed ID: 25363763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
    Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
    Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8
    Lake CM; Voss K; Bauman BM; Pohida K; Jiang T; Dveksler G; Snow AL
    Cell Death Dis; 2021 Apr; 12(4):400. PubMed ID: 33854046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
    Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
    Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIM-3 and CEACAM1 do not interact in cis and in trans.
    De Sousa Linhares A; Kellner F; Jutz S; Zlabinger GJ; Gabius HJ; Huppa JB; Leitner J; Steinberger P
    Eur J Immunol; 2020 Aug; 50(8):1126-1141. PubMed ID: 32222966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
    Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
    Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma.
    Yang F; Zeng Z; Li J; Ren X; Wei F
    Front Mol Biosci; 2021; 8():619765. PubMed ID: 34368221
    [No Abstract]   [Full Text] [Related]  

  • 12. Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection.
    Dong J; Yang XF; Wang LX; Wei X; Wang AH; Hao CQ; Shen HJ; Huang CX; Zhang Y; Lian JQ
    Front Cell Infect Microbiol; 2017; 7():98. PubMed ID: 28401068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
    Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
    Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor antigen-specific CD8
    Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
    Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.
    Takano S; Saito H; Ikeguchi M
    Surg Today; 2016 Nov; 46(11):1341-7. PubMed ID: 26801344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
    Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis.
    Piancone F; Saresella M; Marventano I; La Rosa F; Caputo D; Mendozzi L; Rovaris M; Clerici M
    J Immunol; 2019 Jul; 203(1):76-83. PubMed ID: 31142599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor.
    Hajihassan Z; Mohammadpour Saray M; Yaseri A
    Iran Biomed J; 2023 Jul; 27(4):191-8. PubMed ID: 37525418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
    Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.